bluuebunny/crossref_metadata_2025_split huggingface dataset:
Large Congenital Melanocytic Nevus on the Breast Sparing the Nipple and Areola
Authors: Baykal Can , Solakoğlu Seyhun , Polat Ekinci Algün , Yazganoğlu Kurtuluş Didem 
Published: May 2015

AbstractBackgroundDivided nevus is a rare entity that has been described for a special appearance of congenital melanocytic nevi (CMNs) occurring on the eyelid and penis. It is presumed that the formation of divided nevi is related with the embryologic development of the eyelid and penis, thus giving a hint about the occurrence time of CMN in utero. This article focuses on a formerly undescribed observation of another special clinical appearance of CMN discussing possible relation with embryogenesis.MethodsThe data including photographic documentations of a total number of 86 patients with large CMN seen in a single center were reviewed according to the involvement of the nipple and areola by the main mass of the nevus and associated satellite lesions.ResultsEight patients presented with CMNs involving one (n=6) or both (n=2) breast region. In all of them, CMN surrounded the nipple‐areola complex without involving these structures. Furthermore, satellite nevi have not been observed on the nipple and areola in any of the 86 patients.ConclusionWe presume that different developmental time periods of the breast and the nipple–areola complex and the occurrence of the melanocytic lesion before the embryologic development of nipple–areola complex could explain our observation of CMN sparing the nipple–areola complex. The term “nipple‐sparing nevus of the breast” is suggested for this special clinical appearance of CMN.
First report in a dog model of atopic dermatitis: expression patterns of protease‐activated receptor‐2 and thymic stromal lymphopoietin
Authors: Kim Ha‐Jung , Ahrens Kim , Park Hee‐Myung , Marsella Rosanna 
Published: May 2015

BackgroundProtease‐activated receptor (PAR)‐2 plays a crucial role in inflammation and the skin barrier. Protease‐activated receptor‐2 is activated by proteolytic enzymes of allergens and stimulates thymic stromal lymphopoietin (TSLP), promoting T‐helper 2 cytokines. In humans with atopic dermatitis (AD), increased expression of PAR‐2 and TSLP has been reported.Hypothesis/ObjectivesTo compare the pattern of staining of PAR‐2 and TSLP between normal and atopic beagle dogs. The hypothesis tested was that increased expression is present in atopic dog skin compared with healthy control skin.AnimalsEight atopic and five normal dogs were challenged for 3 days with house dust mites.MethodsSkin biopsies were taken to measure the intensity, distribution, integrity and cell staining pattern on days 0, 3 and 10, both objectively and subjectively. Clinical signs were scored and compared between groups.ResultsAtopic dogs showed a significant increase in clinical scores on days 3 (peak of challenge) and 10 (resolution) and a significant condensed staining pattern for TSLP in the stratum basale at all times in comparison to normal dogs. They showed a significant patchy pattern for PAR‐2 on days 0 and 3 and for TSLP at all times compared with normal dogs. The intensity itself was not significantly increased in atopic dogs compared with normal animals for both PAR‐2 and TSLP.Conclusions and clinical importanceThese preliminary findings do not confirm a difference in the amount of expression but rather in its pattern. Studies using PAR‐2 or TSLP inhibitors could shed light on their clinical relevance.
Oclacitinib in feline nonflea‐, nonfood‐induced hypersensitivity dermatitis: results of a small prospective pilot study of client‐owned cats
Authors: Ortalda Christian , Noli Chiara , Colombo Silvia , Borio Stefano 
Published: May 2015

BackgroundOclacitinib is a Janus kinase inhibitor that decreases pruritus and lesions in allergic dogs. In cats, it is able to inhibit interleukin‐31‐induced pruritus; no information is available on its clinical effectiveness.Hypothesis/ObjectivesTo evaluate the efficacy, ease of administration and tolerability of oclacitinib in feline nonflea‐, nonfood‐induced hypersensitivity dermatitis.MethodsCats >12 months of age and >3 kg body weight with a diagnosis of nonflea‐, nonfood‐induced hypersensitivity dermatitis were treated with oclacitinib, 0.4–0.6 mg/kg orally (p.o.) twice daily for 2 weeks, then once daily for an additional 14 days. Clinical lesions were evaluated with the Scoring Feline Allergic Dermatitis (SCORFAD) system and pruritus was evaluated with a 10‐cm‐long visual analog scale (VAS) before and at the end of the study. Owners assessed global efficacy, ease of administration and tolerability with a four‐point scale.ResultsTwelve cats were treated with a mean initial oclacitinib dose of 0.47 mg/kg p.o. twice daily. There was good improvement in SCORFAD and VAS pruritus scores in five of 12 cases, while the other cats were unchanged, deteriorated or dropped out due to treatment failure. Owners scored global efficacy as good/excellent in four of 12 cases and ease of administration and tolerability as good/excellent in 10 of 12.Conclusions and clinical importanceOclacitinib at 0.4–0.6 mg/kg p.o. may be an effective and safe drug for some cats with nonflea‐, nonfood‐induced hypersensitivity dermatitis. Further studies are needed to identify the most effective dose range for this species.
Abstract 1446: Isolation of a novel metastasis-related microRNA, miR-518c-5p, induced by the stromal cell-derived factor (SDF)-1/CXCR4 system in oral cancer
Authors: Kinouchi Makoto , Uchida Daisuke , Kuribayashi Nobuyuki , Tamatani Tetsuya , Nagai Hirokazu , Miyamoto Youji 
Published: May 2015

Abstract
We have demonstrated that stromal-cell derived factor (SDF)-1/CXCR4 system is involved in the metastatic process of oral cancer. Recently, small non coding RNAs, microRNAs (miRNAs) are involved in the metastatic process of several types of cancers. However, the miRNAs contributed to metastases induced by the SDF-1/CXCR4 system in oral cancer are largely unknown. Thus, we examined the metastasis-related miRNAs induced by the SDF-1/CXCR4 system, using oral cancer cells, B88-SDF-1 which exhibits functional CXCR4 and distant metastatic potential, in vivo.
We examined metastasis-related miRNAs induced by the SDF-1/CXCR4 system using miRNA microarray analysis. Among these miRNAs, we confirmed the upregulation of miR-518c-5p in B88-SDF-1 cells by the real-time PCR analysis. Although LNA-based miR518c-5p inhibitor did not affect the cell growth, but did significantly inhibit the migration of B88-SDF-1 cells. Next, we transfected miR-518c expression vector into parental B88 cells, and isolated stable transfectant, B88-518c. The anchorage dependent and independent growth of B88-518c cells were significantly enhanced in compared with those of mock cells. Moreover, we could detect the enhanced migration of B88-518c cells. LNA-based miR-518c-5p inhibitor significantly impaired the enhanced cell growth and migration of B88-518c cells, indicating that these phenomenon were dependent on the expression of miR-518c-5p, not on that of miR-518c-3p. Next, we examined the function of miR-518c-5p in vivo. B88-518c cells or mock cells were inoculated into the masseter muscle or the blood vessels of nude mice. Tumor volume, lymph nodes metastasis, and lung metastasis were significantly increased in the mice inoculated with B88-518c cells. These results indicate that SDF-1/CXCR4 system regulates the metastases of oral cancer via induction of miR-518c-5p.
Citation Format: Makoto Kinouchi, Daisuke Uchida, Nobuyuki Kuribayashi, Tetsuya Tamatani, Hirokazu Nagai, Youji Miyamoto. Isolation of a novel metastasis-related microRNA, miR-518c-5p, induced by the stromal cell-derived factor (SDF)-1/CXCR4 system in oral cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1446. doi:10.1158/1538-7445.AM2014-1446
Abstract 1473: Indentification of microRNA signature and deregulation in breast, lung and colon cancer through next generation sequencing and quantitative reverse transcriptase PCR
Authors: Liu Chunmei 
Published: May 2015

Abstract
Global alterations of microRNA expression have been described in a large number of malignancies and microRNA signatures have been used as classifier for diagnosis, prognosis and therapeutic response in cancer. In current study, we compared the global patterns of microRNA expression in breast cancer, lung cancer and colon cancer patients with their normal adjacent tissues through next generation sequencing (NGS). Differentially expressed microRNAs such as let-7 family, miR34 family, miR21 and miR29 family, miR17, miR92a, miR205, miR145 as well as other signature microRNAs were further validated through quantitative reverse transcriptase PCR (qRT-PCR). Since microRNAs do not function in isolation, we also compared the expression level of possible targeted mRNAs such as target s for Let-7 family, HMGA2 (high mobility group AT-hook2) , RAS, KRAS; targets for miR-34, SNAIL(zinc finger protein) , Wnt1, SIRT1 and CDK6; targets for miR-21 , tropomyosin (TPM1), PDCD4 and PTEN; targets for MiR29 family, MCL1, KLF4 through qRT-PCR.
Note: This abstract was not presented at the meeting.
Citation Format: Chunmei Liu. Indentification of microRNA signature and deregulation in breast, lung and colon cancer through next generation sequencing and quantitative reverse transcriptase PCR. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1473. doi:10.1158/1538-7445.AM2014-1473
Abstract 1476: Hypermethylation of a TGF-β regulated micro-RNA, miR-193a, predicts prognosis in ovarian cancer
Authors: Cheng Frank Hsueh-Che , Chen Gary C.W. , Chou Jian-Liang , Lin Ya-Wen , Chen Lin-Yu , Lai Hung-Cheng , Li Chin , Chan Michael W.Y. 
Published: May 2015

Abstract
Ovarian cancer is one of the most lethal cancers in the female reproductive system. One of the hypotheses suggests that ovarian cancer arises from cancer stem/progenitor cell with surface antigen CD117 (or c-kit). In order to identify microRNAs (miRNAs) that can regulate the expression of c-kit, bioinformatic prediction was performed and identified miR-193a as one of the regulators. Expression analysis showed that miR-193a was up-regulated upon TGF-β treatment in immortalized ovarian surface epithelial cells (IOSE) cells. On the contrary, expression of miR-193a cannot be detected in a panel of ovarian cancer cell lines (SKOV3, A2780, CP70, MCP2, MCP3). Bisulphite pyrosequencing revealed that promoter CpG island of miR-193a was not methylated in IOSE cell but hypermethylated in the ovarian cancer cells showing down-regulation of miR-193a. Treatment of 5azaDC, a DNMT inhibitor, partially restored miR-193a expression in the ovarian cancer cells, thus suggesting DNA hypermethylation may be responsible for the down-regulation of miR-193a in ovarian cancer. Further clinical studies using bisulphite pyrosequencing found that promoter region of miR-193a was heavily methylated in 109 ovarian cancer patient samples but not in normal OSE samples. Kaplan-meier analysis revealed that patients with higher methylation of miR-193a was significantly associated with shorter overall survival and progression-free survival. Taken together, miR-193a may be a TGF-β regulated tumor suppressor micro-RNA and is epigenetically silenced in ovarian cancer. Methylation of miR-193a may be able to predict prognosis in ovarian cancer patients.
Citation Format: Frank Hsueh-Che Cheng, Gary C.W. Chen, Jian-Liang Chou, Ya-Wen Lin, Lin-Yu Chen, Hung-Cheng Lai, Chin Li, Michael W.Y. Chan. Hypermethylation of a TGF-β regulated micro-RNA, miR-193a, predicts prognosis in ovarian cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1476. doi:10.1158/1538-7445.AM2014-1476
Abstract 1488: Association between microrna binding site polymorphism and susceptibility to colorectal cancer in Korean population
Authors: Kang Byung Woog , Jeon Hyosung , Chae Yee Soo , Lee Soo Jung , Kim Jong Gwang , Lee Hyunchul , Lee Eun-Jin , Lee Myung Hoon , Park Jae Yong , Choi Gyu Seog , Park Jun Seok 
Published: May 2015

Abstract
Background : MicroRNAs (miRNAs) play an important role in the colorectal cancer tumorigenesis by regulation of gene expression through binding to 3′ untranslational region (UTR) of target gene. Single nucleotide polymorphism (SNP) within 3′UTR of gene could be affected by miRNA binding. Docking protein 3 (DOK3) is adapter protein that acts as tumor suppressor through modulating tyrosine kinase signaling.
Methods : One hundred thirty five SNPs were selected in Silico analysis for the current study from 3′UTR SNPs of SNP database, which was based on several miRNA database, calculating miRNA bind efficiency on polymorphism, and HapMap database. Here independent two set of study was designed, 380 healthy controls and 371 colorectal adenocarcinoma patients were enrolled in discovery set, and 524 healthy controls and 521 colorectal adenocarcinoma patients were enrolled in replication set. The SNP genotyping was performed using the Sequenom MassARRAY
Result: In discovery set, 16 SNPs were significantly associated with colorectal cancer in any genetic model from 135 SNP genotyping. Among 16 SNPs, DOK3 rs2279398G&gt;A was significantly associated in replication set recessive model (adjusted odds ratio (OR) = 0.65, 95% confidence interval (CI) = 0.44-0.97, P = 0.03). In combined analysis, DOK3 rs2279398G&gt;A was associated with significantly decreased risk of colorectal cancer in codominant and recessive model (adjusted OR = 0.84, 95% CI = 0.73-0.96, P = 0.012, adjusted OR = 0.65, CI = 0.49-0.88, P = 0.004, respectively).
Conclusion : DOK3 rs2279398G&gt;A may affect the expression of DOK3 by altering miRNA binding efficiency on miRNA-binding sites of the 3′-UTR of DOK3 and impact on colorectal cancer tumorigenesis. This finding suggests that DOK3 rs2279398G&gt;A may be a useful biomarker for determining the susceptibility to colorectal cancer.
Citation Format: Byung Woog Kang, Hyosung Jeon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Hyunchul Lee, Eun-Jin Lee, Myung Hoon Lee, Jae Yong Park, Gyu Seog Choi, Jun Seok Park. Association between microrna binding site polymorphism and susceptibility to colorectal cancer in Korean population. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1488. doi:10.1158/1538-7445.AM2014-1488
Abstract 1499: Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome
Authors: Choi Yunsuk , Hur Eun-Hye , Moon Ju Hyun , Goo Bon-Kwan , Choi Dae R. , Lee Je-Hwan 
Published: May 2015

Abstract
Introduction: MicroRNAs (miRNAs) are short non-coding RNAs that are involved in post-transcriptional regulation of gene expression, which may result in translational inhibition or destabilization of the target mRNA. Various alterations of miRNA expression have been reported in myelodysplastic syndrome (MDS). We aimed to investigate the unique patterns and prognostic significance of miRNA expression in Korean patients with MDS.
Materials and Methods: Bone marrow mononuclear cells were collected from 10 healthy controls and 26 MDS patients, and miRNAs were isolated using a miRNeasy isolation kit (Qiagen) according to the manufacturer's instructions. Quantitative real-time PCR for selected miRNAs including miR-21, miR-124a, miR-126, miR-146b, miR-155, miR-200c, miR-342-5p, miR-708, and Let-7a was performed using a miScript SYBR green PCR kit (Qiagen). RNU6 was used to normalize the miRNA values of all RNA samples. Calculations were made using the comparative Ct (2-ΔΔCt ) method.
Results: Eleven patients with early stage MDS (2 RA, 1 RARS, and 8 RCMD), 10 patients with advanced MDS (3 RAEB-1 and 7 RAEB-2), 4 patients with unknown subtype of MDS, and 1 patient with chronic myelomonocytic leukemia were included in this study. Median age was 58.5 years (range, 13-76). MiR-124a, miR-155, miR-200c, miR-342-5p, and let-7a were significantly under-expressed in MDS patients compared to healthy controls. Levels of miR-124, miR-146b, and miR-155 transcripts were significantly lower in patients with early stage MDS than in those with advanced MDS. Secondary MDS patients (n=6) showed significantly under-expressed MiR-146b and miR-342-5p transcript levels than de novo MDS patients (n=19) (p=0.009 and p=0.043, respectively). We failed to find statistically significant survival differences according to the expression levels of miRNAs, although high expression of miR-124, miR-126, miR-155 and low expression of miR-342-5p tended to be associated with poor overall survival and leukemia free survival.
Conclusion: We first report under-expression of miR-200c in MDS patients. Expression of miRNAs appears to be different according to the stage of MDS. Further investigations are needed to evaluate genetic functions and prognostic significances of miRNAs in MDS.
Citation Format: Yunsuk Choi, Eun-Hye Hur, Ju Hyun Moon, Bon-Kwan Goo, Dae Ro Choi, Je-Hwan Lee. Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1499. doi:10.1158/1538-7445.AM2014-1499
Abstract 1500: The difference of serum RNA profile: RNA detection method
Authors: Kondo Satoshi , Takizawa Satoko , Akiyama Hideo 
Published: May 2015

Abstract
Serum miRNA profiles are widely reported by many research groups, but they do not always coincide well. The reason of this difference is suggested to be, at least in some cases, due to a difference in the RNAdetection method. In this report, we compare the miRNA expression data obtained by different detection tools.. In these days, the whole miRNA expression profiling can be done by multiple qRT-PCR, microarrays, and Next Generation Sequencing. However, the feature of each method will reflect to the obtained data and it is no surprise that data obtained by different tools do not match perfectly. We will compare the serum miRNA expression profiles detected by (1) “TaqMan” Array MicroRNA Card (2) QIAGEN miScript miRNA PCR Array (3) “3D-Gene” Human miRNA oligo chip, (4)”HiSeq” Next Generation Sequencer (5) Nanostring “nCounter” Analysis system and discuss the base of method for serum miRNA profiling.
Citation Format: Satoshi Kondo, Satoko Takizawa, Hideo Akiyama. The difference of serum RNA profile: RNA detection method. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1500. doi:10.1158/1538-7445.AM2014-1500
Abstract 1519: Targeted enrichment and next generation sequencing of non-small cell lung carcinoma FFPE samples
Authors: Breuil Rusla du , Shvetsova Tatiana , Patel Kruti , Moore Troy , Fewell Gwen 
Published: May 2015

Abstract
Targeted enrichment is a powerful tool used for identifying genetic variations that underlie cancer and complex diseases. Current methodologies utilize hybridization probes or PCR to enrich for protein coding regions of a genome followed by deep sequencing. Most of these targeting methods fail to achieve the specificity, coverage and uniformity that are critical for accurate detection and analysis of genetic variability. Nested Patch PCR™ was developed to overcome these pitfalls with highly specific on-target sequence interrogation across hundreds of genomic regions in a single-tube format. This novel technology enables rapid detection of various genetic variations (i.e. SNPs, indels) across a large number of samples, including FFPE (formalin-fixed paraffin embedded) samples which are typically difficult to analyze due to low yield and quality of DNA. To show the utility of TargetRich technology, an enrichment panel was designed targeting NRAS, PTEN, KRAS, ALK, PIK3CA, KIT, BRAF and EGFR to interrogate 250 non-small cell lung carcinoma FFPE samples. The panel was designed against 19.8kb, 134 exons, with 99.9% coverage. A minimum of 50ng FFPE DNA were run for each sample on an Illumina Miseq and the resulting data was comparable to high molecular weight DNA in uniformity and performance; supporting TargetRich® as a sensitive and robust platform to analyze FFPE samples.
Citation Format: Rusla du Breuil, Tatiana Shvetsova, Kruti Patel, Troy Moore, Gwen Fewell. Targeted enrichment and next generation sequencing of non-small cell lung carcinoma FFPE samples. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1519. doi:10.1158/1538-7445.AM2014-1519
Abstract 1528: Identification of FGFR3 as a potential therapeutic target gene for human clear cell ovarian cancer by global genomic analysis
Authors: Tsang Tsun Yee , Mohapatra Gayatry , Itamochi Hiroaki , Mok Samuel C. , Birrer Michael J. 
Published: May 2015

Abstract
Clear cell ovarian cancer (CCOC) is the second most common subtype of ovarian cancer after serous ovarian cancer. CCOC is more resistant to standard chemotherapy and has a poorer prognosis than serous and endometrioid histotypes. We attempted to identify genes that are responsible for the aggressive behavior of CCOC and could be potential therapeutic targets using genomic and expression profilings. To identify gene amplification, genome-wide DNA copy number alterations were measured in 13 CCOC cell lines using high-resolution oligonucleotide array CGH (Agilent 105k Human Genome CGH Microarray). GISTIC analysis identified 16 amplified regions containing 391 genes. After comparison to our database of differentially expressed genes between human CCOC specimens and normal ovarian surface epithelium specimen (Affymetrix U133 Plus 2.0 microarrays), 45 of the amplified genes showed mRNA overexpression in CCOC specimens. Among the 45 genes, fibroblast growth factor receptor 3 (FGFR3) was amplified in 9/13 CCOC cell lines and was overexpressed (12.9 folds) in CCOC specimens. Analysis using PathwayStudio software identified FGFR3 mediated pathways for cell migration and cell proliferation. Knockdown of FGFR3 by transfection with FGFR3 specific shRNAs suppressed cell migration in KOC-7c and HAC-2 cells. Moreover, knockdown of FGFR3 also suppressed anchorage-dependent cell proliferation of KOC-7c and HAC-2 cells. The results from the present study therefore suggested that FGFR3 may promote metastasis and growth of cancer cells and may serve as a potential target gene for treatment of human clear cell ovarian cancer.
Citation Format: Tsun Yee Tsang, Gayatry Mohapatra, Hiroaki Itamochi, Samuel C. Mok, Michael J. Birrer. Identification of FGFR3 as a potential therapeutic target gene for human clear cell ovarian cancer by global genomic analysis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1528. doi:10.1158/1538-7445.AM2014-1528